Safe, well tolerated, affordable, and effective medications are urgently needed against SARS-CoV-2 and its emerging vaccine resistant mutant strains. Pathogenics Inc. is currently developing N-Chlorotaurine (NCT) as a medication for the treatment of mild to severe COVID-19 cases and other infections.
NCT helps fight COVID-19 by directly killing the SARS-CoV-2 virus, controlling inflammation, preventing secondary infections/thrombosis, and protecting living cells by supplying an essential antioxidant through its primary byproduct, the amino acid taurine.
Unlike antibiotics or vaccines (antibodies) which only target specific pathogens, the non-specific way NCT inactivates pathogens prevents them from ever becoming resistant to it.
The clinical disease course of COVID-19 begins with a respiratory infection by the SARS-CoV-2 virus, which eventually activates the human innate immune response to kill the virus, and this triggers inflammation to help fight the infection. However, this inflammation can rapidly change from being helpful to harmful, and trigger the mortal danger known as the “cytokine storm”. So the key to treating a COVID-19 infection is killing the virus while controlling inflammation.